Marc B. Garnick, MD, and E. David Crawford, MD, presented “Cardiovascular Complications in Patients Undergoing ADT” for the Grand Rounds in Urology audience in March 2023.

How to cite: Garnick, Marc B. Crawford, E. David. “Cardiovascular Complications in Patients Undergoing ADT” February 2023. Accessed Jul 2024.

Cardiovascular Complications in Patients Undergoing ADT – Summary

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, discusses cardiovascular (CV) issues in patients on androgen deprivation therapy (ADT) with Marc B. Garnick, MD, the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center. Dr. Crawford begins by listing the side effects of ADT, the most significant of which are hypertension and weight gain before inviting Dr. Garnick to comment on the future of ADT. Dr. Garnick offers a brief history of CV issues that arise during systemic therapies for prostate cancer and notes that only recently has an interest in understanding the pathophysiology of CV risk factors developed. Previously, it was assumed that pre-existing cardiovascular disease caused any related morbidities or mortality. Now it is clear that both LHRH agonists and GNHR antagonists are associated with CV risks.  Dr. Garnick emphasizes that CV complications from ADT can offset the success of cancer treatment. As such, it is important to assess the patient’s cardiovascular history and to address the patient’s safety during ongoing androgen deprivation therapy. Dr. Garnick concludes that a more comprehensive approach to identifying the leading causes of morbidity and mortality in patients with prostate cancer is needed.

For more on the role of ADT in prostate cancer, visit our Next Generation ADT Learning Center.


Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where he also directs the hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has dedicated his career to the development of new therapies for prostate cancer. He serves as the Editor-in-Chief for The Annual Report on Prostate Diseases, formerly Perspectives on Prostate Disease. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron). In addition to his academic affiliations, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research at Beth Israel Deaconess Medical Center, serves as medical adviser to World Book Encyclopedia, and is an active advisory member of several FDA panels and advisory committees. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and of Penn Medicine. Dr. Garnick is also a Trustee Emeritus of Bowdoin College in Brunswick, Maine.